Exactech has exclusively licensed new software from Advata that will extend the capabilities of its innovative machine learning (ML)-based clinical decision support tool, Predict+. This newly licensed software will combine with the company’s Active Intelligence platform that will further facilitate Predict+ integration with the Equinoxe Planning App, and will also encourage integration with other software and databases.
Developed in partnership with Advata in 2019 and released in November 2020, Predict+ is a data-driven, clinical decision support tool and reportedly the first software of its kind to use ML to generate personalized risk-benefit analyses to help predict patient outcomes after shoulder replacement surgery. This software was designed to better inform surgeons regarding the expected outcomes that can be achieved after shoulder replacement, based on the clinical experience documented within the world’s largest single-shoulder prosthesis outcomes database of more than 15,000 patients. These personalized predictions are designed to quantify the risk and benefit that an individual patient may experience after anatomic and reverse shoulder replacement.
Additionally, Exactech has hired a team of machine learning researchers and engineers that will further accelerate Exactech’s ML research and development capabilities and improve its ability to produce additional innovative artificial intelligence-based software for various orthopedic applications.
Predict+ is built upon previously published, peer-reviewed research and is accessible through the Equinoxe Planning App preoperative planning software, which can be used with the ExactechGPS navigation system in the operating room, connecting the preoperative plan with implant placement. Predict+ is available to surgeons globally on a limited basis.
Exactech has exclusively licensed new software from Advata that will extend the capabilities of its innovative machine learning (ML)-based clinical decision support tool, Predict+. This newly licensed software will combine with the company’s Active Intelligence platform that will further facilitate Predict+ integration with the Equinoxe Planning...
Exactech has exclusively licensed new software from Advata that will extend the capabilities of its innovative machine learning (ML)-based clinical decision support tool, Predict+. This newly licensed software will combine with the company’s Active Intelligence platform that will further facilitate Predict+ integration with the Equinoxe Planning App, and will also encourage integration with other software and databases.
Developed in partnership with Advata in 2019 and released in November 2020, Predict+ is a data-driven, clinical decision support tool and reportedly the first software of its kind to use ML to generate personalized risk-benefit analyses to help predict patient outcomes after shoulder replacement surgery. This software was designed to better inform surgeons regarding the expected outcomes that can be achieved after shoulder replacement, based on the clinical experience documented within the world’s largest single-shoulder prosthesis outcomes database of more than 15,000 patients. These personalized predictions are designed to quantify the risk and benefit that an individual patient may experience after anatomic and reverse shoulder replacement.
Additionally, Exactech has hired a team of machine learning researchers and engineers that will further accelerate Exactech’s ML research and development capabilities and improve its ability to produce additional innovative artificial intelligence-based software for various orthopedic applications.
Predict+ is built upon previously published, peer-reviewed research and is accessible through the Equinoxe Planning App preoperative planning software, which can be used with the ExactechGPS navigation system in the operating room, connecting the preoperative plan with implant placement. Predict+ is available to surgeons globally on a limited basis.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
